What is the recommended dosage of Rosuvastatin ( Crestor ) for treating hyperlipidemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The recommended dosage of Rosuvastatin (Crestor) for treating hyperlipidemia is 5-40 mg daily, with high-intensity statin therapy using 20-40 mg for patients who require greater LDL-cholesterol reduction.

Key Considerations

  • The dosage can be adjusted based on the patient's response to therapy and their individual risk factors for cardiovascular disease 1.
  • For patients with mild to moderate kidney disease, no dose modification is necessary, but for those with severe kidney disease (creatinine clearance < 30 mL/min/1.73 m²), the dose should not exceed 10 mg daily 1.
  • Rosuvastatin should be taken at the same time each day, with or without food, and lipid levels should be checked 2-4 weeks after starting therapy to assess response.
  • The medication works by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol production and increasing LDL receptor activity in the liver, which removes more LDL from circulation.

Important Factors

  • The patient's age, presence of other cardiovascular risk factors, and type of diabetes (if applicable) should be considered when determining the optimal dosage of Rosuvastatin 1.
  • Patients under the age of 40 years and/or who have type 1 diabetes with other ASCVD risk factors should discuss the relative benefits and risks with their healthcare provider and consider the use of moderate-intensity statin therapy.
  • The maximum approved dose is 40 mg daily, which is reserved for patients with severe hypercholesterolemia who don't achieve their lipid goals at lower doses.

Dosage Adjustments

  • Dose adjustments may be needed for elderly patients or those with kidney impairment 1.
  • For patients needing greater LDL-cholesterol reduction (more than 50%), therapy may be started at 20 mg daily 1.

From the FDA Drug Label

The dosage range for rosuvastatin tablets is 5 mg to 40 mg orally once daily. The recommended dose of rosuvastatin tablets depends on a patient’s indication for usage, LDL-C, and individual risk for CV events.

The recommended dosage of Rosuvastatin (Crestor) for treating hyperlipidemia is between 5 mg to 40 mg orally once daily, with the specific dose depending on the patient's indication for usage, LDL-C levels, and individual risk for CV events 2.

  • The dose should be adjusted if necessary, with LDL-C levels assessed when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets.
  • It is essential to consider the patient's overall CV risk profile when determining the optimal dosage.

From the Research

Rosuvastatin Dosage for Hyperlipidemia

The recommended dosage of Rosuvastatin (Crestor) for treating hyperlipidemia can vary depending on the patient's condition and risk factors.

  • The dosage of rosuvastatin can range from 10-40 mg per day, as seen in studies where the combination of rosuvastatin 10-40 mg and ezetimibe 10 mg enabled considerable reductions in LDL-C (up to 60-75%) with a good safety profile in a broad spectrum of patients with hypercholesterolemia 3.
  • In patients with high atherosclerotic cardiovascular disease risk, a moderate-intensity rosuvastatin with ezetimibe combination (rosuvastatin 10 mg/ezetimibe 10 mg) was non-inferior to high-intensity rosuvastatin (rosuvastatin 20 mg) in reducing LDL-C levels 4.
  • The efficacy and safety of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg have been compared to simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients, with results showing that rosuvastatin/ezetimibe combinations achieved significant improvements in lipid profiles 5.
  • A fixed-dose combination of rosuvastatin/ezetimibe has been shown to be effective in reducing LDL-C and total cholesterol in adults with hypercholesterolemia, with a similar safety profile to rosuvastatin monotherapy and simvastatin/ezetimibe 6.
  • The combination of rosuvastatin and ezetimibe has complementary mechanisms of action that enhance their ability to reduce LDL-C levels, and may improve adherence to medication 3, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.